<VariationArchive VariationID="2018042" VariationName="NM_000152.5(GAA):c.2702dup (p.Gln902fs)" VariationType="Duplication" Accession="VCV002018042" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-20" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2075959" VariationID="2018042">
      <GeneList>
        <Gene Symbol="GAA" FullName="alpha glucosidase" GeneID="2548" HGNC_ID="HGNC:4065" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17q25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="80101581" stop="80119881" display_start="80101581" display_stop="80119881" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NW_025791802.1" start="126287" stop="144587" display_start="126287" display_stop="144587" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="78075354" stop="78093678" display_start="78075354" display_stop="78093678" Strand="+" />
          </Location>
          <OMIM>606800</OMIM>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000152.5(GAA):c.2702dup (p.Gln902fs)</Name>
      <CanonicalSPDI>NC_000017.11:80118707:T:TT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>17q25.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="80118707" stop="80118708" display_start="80118707" display_stop="80118708" variantLength="1" positionVCF="80118707" referenceAlleleVCF="C" alternateAlleleVCF="CT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="78092506" stop="78092507" display_start="78092506" display_stop="78092507" variantLength="1" positionVCF="78092506" referenceAlleleVCF="C" alternateAlleleVCF="CT" />
      </Location>
      <ProteinChange>Q902fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.78092507dup" Assembly="GRCh37">
            <Expression>NC_000017.10:g.78092507dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.80118708dup" Assembly="GRCh38">
            <Expression>NC_000017.11:g.80118708dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009822.1" sequenceAccession="NG_009822" sequenceVersion="1" change="g.22153dup">
            <Expression>NG_009822.1:g.22153dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000152.5" sequenceAccession="NM_000152" sequenceVersion="5" change="c.2702dup" MANESelect="true">
            <Expression>NM_000152.5:c.2702dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000143.2" sequenceAccession="NP_000143" sequenceVersion="2" change="p.Gln902fs">
            <Expression>NP_000143.2:p.Gln902fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001079803.3" sequenceAccession="NM_001079803" sequenceVersion="3" change="c.2702dup">
            <Expression>NM_001079803.3:c.2702dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001073271.1" sequenceAccession="NP_001073271" sequenceVersion="1" change="p.Gln902fs">
            <Expression>NP_001073271.1:p.Gln902fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001079804.3" sequenceAccession="NM_001079804" sequenceVersion="3" change="c.2702dup">
            <Expression>NM_001079804.3:c.2702dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001073272.1" sequenceAccession="NP_001073272" sequenceVersion="1" change="p.Gln902fs">
            <Expression>NP_001073272.1:p.Gln902fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001406741.1" sequenceAccession="NM_001406741" sequenceVersion="1" change="c.2702dup">
            <Expression>NM_001406741.1:c.2702dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001393670.1" sequenceAccession="NP_001393670" sequenceVersion="1" change="p.Gln902Alafs">
            <Expression>NP_001393670.1:p.Gln902Alafs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001406742.1" sequenceAccession="NM_001406742" sequenceVersion="1" change="c.2702dup">
            <Expression>NM_001406742.1:c.2702dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001393671.1" sequenceAccession="NP_001393671" sequenceVersion="1" change="p.Gln902Alafs">
            <Expression>NP_001393671.1:p.Gln902Alafs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_673" sequenceAccession="LRG_673">
            <Expression>LRG_673:g.22153dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_673t1" sequenceAccession="LRG_673t1">
            <Expression>LRG_673t1:c.2702dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_673p1" sequenceAccession="LRG_673p1" change="p.Gln902Alafs">
            <Expression>LRG_673p1:p.Gln902Alafs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000152.5(GAA):c.2702dup (p.Gln902fs) AND Glycogen storage disease, type II" Accession="RCV002870711" Version="2">
        <ClassifiedConditionList TraitSetID="1104">
          <ClassifiedCondition DB="MedGen" ID="C0017921">Glycogen storage disease, type II</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-07-19" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-07-19" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">22252923</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29122469</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31606152</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33741225</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1104" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1936" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">GLYCOGENOSIS, GENERALIZED, CARDIAC FORM</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GSD II</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POMPE DISEASE</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Glycogen storage disease, type II</ElementValue>
                <XRef ID="Glycogen+Storage+Disease+Type+2/3122" DB="Genetic Alliance" />
                <XRef ID="237967002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycogen Storage Disease Type II (Pompe Disease)</ElementValue>
                <XRef ID="NBK1261" DB="GeneReviews" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycogen storage disease type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acid maltase deficiency disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Aglucosidase alfa</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha-1,4-glucosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cardiomegalia glycogenica diffusa</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Deficiency of alpha-glucosidase</ElementValue>
                <XRef ID="124462004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Deficiency of lysosomal alpha-glucosidase</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucosidase acid-1,4-alpha deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ACID ALPHA-GLUCOSIDASE DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">AMD</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">GSD2</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Pompe disease is classified by age of onset, organ involvement, severity, and rate of progression. Infantile-onset Pompe disease (IOPD; individuals with onset before age 12 months with cardiomyopathy) may be apparent in utero but more typically onset is at the median age of four months with hypotonia, generalized muscle weakness, feeding difficulties, failure to thrive, respiratory distress, and hypertrophic cardiomyopathy. Without treatment by enzyme replacement therapy (ERT), IOPD commonly results in death by age two years from progressive left ventricular outflow obstruction and respiratory insufficiency. Late-onset Pompe disease (LOPD; including: (a) individuals with onset before age 12 months without cardiomyopathy; and (b) all individuals with onset after age 12 months) is characterized by proximal muscle weakness and respiratory insufficiency; clinically significant cardiac involvement is uncommon.</Attribute>
                <XRef ID="NBK1261" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2503" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5714" />
                <XRef ID="5714" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301438</ID>
                <ID Source="BookShelf">NBK1261</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2006">
                <ID Source="pmc">3110959</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173338</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Pompe.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Newborn Screening ACT Sheet- Pompe Disease (Glycogen Storage Disease type II), 2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Pompe-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Pompe disease: acid alpha-glucosidase deficiency, 2022</CitationText>
              </Citation>
              <XRef ID="365" DB="Orphanet" />
              <XRef ID="C0017921" DB="MedGen" />
              <XRef ID="MONDO:0009290" DB="MONDO" />
              <XRef Type="MIM" ID="232300" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5911437" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="17124339|MedGen:C0017921" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003221367" DateUpdated="2024-02-20" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-07-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">22252923</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29122469</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31606152</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33741225</ID>
          </Citation>
          <Comment>This sequence change results in a frameshift in the GAA gene (p.Gln902Alafs*116). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 51 amino acid(s) of the GAA protein and extend the protein by 64 additional amino acid residues. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with GAA-related conditions. This variant disrupts a region of the GAA protein in which other variant(s) (p.Tyr928Cys) have been determined to be pathogenic (PMID: 22252923, 29122469, 31606152, 33741225). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.78092506_78092507insT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0017921" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5911437" TraitType="Disease" MappingType="XRef" MappingValue="C0017921" MappingRef="MedGen">
        <MedGen CUI="C0017921" Name="Glycogen storage disease, type II" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

